


WHAT IS CLAIMED IS:

1. A compound of the structural formula I:


5



Formula I

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

- 10 M, M1, and M2, independently are CH or N;



R represents hydrogen, or C₁₋₆ alkyl;

- 15 X represents -(CHR₇)_p-, or a bond;

Y represents -(CH₂)_r-, -CO(CH₂)_n-, -SO₂-, -O-, -S-, -CH(OR')-, or CONR';

- 20 R' represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;

- 25 or, R' and R₆ taken together with the intervening N atom of CONR' of Y to form a 4-10 membered carbocyclic or heterocyclic ring optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-4 double bonds, and optionally substituted by 1-3 groups selected from Ra;

Q represents N, CRY, or O, wherein R₂ is absent when Q is O;

R_Y represents H, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR,

5 -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-5 groups selected from Ra;

10 or, R₂-Q-R₃ form a 3-15 membered carbocyclic or heterocyclic ring or fused ring, optionally interrupted by 1-3 atoms of O, S, C(O) or NR, and optionally having 1-5 double bonds, and optionally substituted by 1-3 groups selected from Ra;

15 R_w represents H, C₁₋₆ alkyl, -C(O)C₁₋₆ alkyl, -C(O)OC₁₋₆ alkyl, -SO₂N(R)₂, -SO₂C₁₋₆ alkyl, -SO₂C₆₋₁₀ aryl, NO₂, CN or -C(O)N(R)₂;

20 R₂ represents hydrogen, C₁₋₁₀ alkyl, C₁₋₆ alkylSR, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁₋₆ alkoxy, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -N(R)₂, -COOR, or -(CH₂)_nC₆₋₁₀ aryl, said alkyl, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;

25 R₃ represents hydrogen, C₁₋₁₀ alkyl, -(CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_nC₃₋₁₀ heterocyclyl, -(CH₂)_nC₅₋₁₀ heteroaryl, -(CH₂)_nCOOR, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_nNHR₈, -(CH₂)_nN(R)₂, -(CH₂)_nNHCOOR, -(CH₂)_nN(R₈)CO₂R, -(CH₂)_nN(R₈)COR, -(CH₂)_nNHCOR, -(CH₂)_nCONH(R₈), aryl, -(CH₂)_nC₁₋₆ alkoxy, CF₃, -(CH₂)_nSO₂R, -(CH₂)_nSO₂N(R)₂, -(CH₂)_nCON(R)₂, -(CH₂)_nCONHC(R)₃, -(CH₂)_nCOR₈, nitro, cyano or halogen, said alkyl, alkoxy, heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups of Ra;

30 R₄ and R₅ independently represent hydrogen, C₁₋₆ alkoxy, OH, OCOR₃, C₁₋₆ alkyl, COOR, SO₃H, O(CH₂)_nN(R)₂, O(CH₂)_nCO₂R, C₁₋₆ alkylcarbonyl, S(O)qRY, (CH₂)_nOPO(OH)₂, O(CH₂)_nOPO(OH)₂, N(R)₂, CF₃, nitro, cyano or halogen where said alkyl, and alkoxy, are optionally substituted with 1-7 groups of Ra;

R₆ represents hydrogen, C₁-10 alkyl, -(CH₂)_nC₆-10 aryl, -(CH₂)_nC₅-10 heteroaryl, (C₆-10 aryl)O-, -(CH₂)_nC₃-10 heterocyclyl, -(CH₂)_nC₃-8 cycloalkyl, -COOR, -C(O)CO₂R, said aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1-3 groups selected from Ra;

5 R₇ represents hydrogen, C₁-6 alkyl, -(CH₂)_nCOOR or -(CH₂)_nN(R)₂,

R₈ represents -(CH₂)_nC₃-8 cycloalkyl, -(CH₂)_n 3-10 heterocyclyl, C₁-6 alkoxy or -(CH₂)_nC₅-10 heteroaryl, said heterocyclyl, aryl or heteroaryl optionally substituted with 1-3 groups selected from Ra;

10 R₉ represents C₁-10 alkyl, -(CH₂)_nC₁-6 alkoxy, -(CH₂)_nC₃-8 cycloalkyl, -(CH₂)_nC₃-10 heterocyclyl, -(CH₂)_nC₆-10 aryl, -(CH₂)_nC₅-10 heteroaryl, or -N(R)₂ wherein said alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl are optionally substituted with 1-3 groups selected from Ra,

15 R^a represents F, Cl, Br, I, CF₃, N(R)₂, NO₂, CN, -COR₈, -CONHR₈, -CON(R₈)₂, -O(CH₂)_nCOOR, -NH(CH₂)_nOR, -COOR, -OCF₃, -NHCOR, -SO₂R, -SO₂NR₂, -SR, (C₁-C₆ alkyl)O-, -(CH₂)_nO(CH₂)_mOR, -(CH₂)_nC₁-6 alkoxy, (aryl)O-, -OH, (C₁-C₆ alkyl)S(O)_m-, H₂N-C(=NH)-, (C₁-C₆ alkyl)C(O)-, (C₁-C₆ alkyl)OC(O)NH-, -(C₁-C₆ alkyl)NR_w(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₁-C₆ alkyl)O(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₁-C₆ alkyl)S(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₁-C₆ alkyl)-C₃-10 heterocyclyl-R_w, -(CH₂)_nZ¹-C(=Z²)N(R)₂, -(C₂-6 alkenyl)NR_w(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)O(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)S(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)-C₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -(CH₂)_nPO(OR)₂, -(CH₂)_nOPO(OR)₂, -O(CH₂)_nSO₂R, -O(CH₂)_nPO(OR)₂, -O(CH₂)_nOPO(OR)₂, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C₂-6 alkenyl, and C₁-C₁₀ alkyl, said alkyl, alkenyl,

20 -(C₂-6 alkenyl)O(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)S(CH₂)_nC₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)-C₃-10 heterocyclyl-R_w, -(C₂-6 alkenyl)-Z¹-C(=Z²)N(R)₂, -(CH₂)_nSO₂R, -(CH₂)_nSO₃H, -(CH₂)_nPO(OR)₂, -(CH₂)_nOPO(OR)₂, -O(CH₂)_nSO₂R, -O(CH₂)_nPO(OR)₂, -O(CH₂)_nOPO(OR)₂, cyclohexyl, morpholinyl, piperidyl, pyrrolidinyl, thiophenyl, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, isothiazolyl, C₂-6 alkenyl, and C₁-C₁₀ alkyl, said alkyl, alkenyl,

25 alkoxy, phenyl, pyridyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, and isothiazolyl optionally substituted with 1-3 groups selected from C₁-C₆ alkyl, COOR, SO₃H, OH, F, Cl, Br, I, and -O(CH₂)_nCH(OH)CH₂SO₃H;

Z¹ and Z² independently represents NR_w, O, CH₂, or S;

30

m is 0-3;


n is 0-3;

q is 0-2;

r is 0-6 and

p is 0-2.

2. A compound according to claim 1 wherein M, M1, and M2 are all CH, or at least one of M, M1 or M2 is N.



5 3. A compound according to claim 2 wherein W represents
represents CHR₇.

4. A compound according to claim 2 wherein W represents (CH₂)_nR₉.

10 5. A compound according to claim 3 wherein Y is -CO(CH₂)_n, -(CH₂)_r or
CH(OR) and Q is N or Ry.

15 6. A compound according to claim 5 wherein R₆ is C₁₋₁₀ alkyl, (CH₂)_nC₆₋₁₀ aryl,
(CH₂)_nC₅₋₁₀ heteroaryl, (CH₂)_nC₃₋₁₀ heterocyclyl, or (CH₂)_nC₃₋₈ cycloalkyl, said aryl, heteroaryl,
heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a, Y is -CO(CH₂)_n, Q is N, and R₂
and R₃ are independently selected from C₁₋₁₀ alkyl, (CH₂)_nC₃₋₈ cycloalkyl, -(CH₂)_n-5~10-membered
heteroaryl, -(CH₂)_nC₆₋₁₀ aryl, -(CH₂)_n-3~10-membered heterocyclyl, and C₁₋₆ alkylOH said cycloalkyl,
aryl, heteroaryl, heterocyclyl and alkyl optionally substituted with 1 to 3 groups of R^a.

20 7. A compound which is:
1-(1-Benzyl-6-methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-benzyl-5-methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(5-Methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
Methyl [2-(2,2-dimethylpropanoyl)-6-methoxy-1H-benzimidazol-1-yl]acetate,
25 Methyl [2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetate,
[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N,N-bis(3-methylbutyl)acetamide,
1-(Diethoxymethyl)-6-methoxy-1H-benzimidazole,
1-(diethoxymethyl)-5-methoxy-1H-benzimidazole,
30 1-(6-Methoxy-1H-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1H-benzimidazol-1-yl]-N,N-diisobutylacetamide,

- 2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
- 5 2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
10 2-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetic acid,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-bis(3-methylbutyl)acetamide,
- 15 10 2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-diisobutylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N,N*-dipropylacetamide,
N-(Cyclopropylmethyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
- 20 15 2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-(3-methylbutyl)acetamide,
N-Butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
N-Cyclohexyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
2-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
N-(3,3-Dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
- 25 20 1-[2-(2,2-Dimethylpropanoyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one, 1-[2-(2,2-Dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(1-Benzyl-5-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-Benzyl-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
25 25 1-[1-(3,3-Dimethylbutyl)-5-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
1-[1-(3,3-Dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl]-2,2-dimethylpropan-1-one,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]acetamide,
N,N-Dibutyl-2-[2-(2,2-dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]acetamide,
1-[2-(2,2-Dimethylpropyl)-5-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
30 30 1-[2-(2,2-Dimethylpropyl)-6-methoxy-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[5-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-[6-Methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
1-(5-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,

- 1-(6-Methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
1-(2-Benzyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)acetamide,
5 *N,N*-dibutyl-2-(2-isobutyryl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)acetamide,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)acetamide,
N,N-dibutyl-2-(8-isobutyryl-2-methoxy-9*H*-purin-9-yl)acetamide,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)acetamide,
10 *N,N*-dibutyl-2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)acetamide,
N,N-dibutyl-2-(2-(2,2-dimethylpropanoyl)-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)acetamide
N,N-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)acetamide,
N,N-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)acetamide,
15 *N,N*-dibutyl-2-(8-(2,2-dimethylpropanoyl)-2-methoxy-9*H*-purin-9-yl)acetamide,
N,N-dibutyl-2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)acetamide,
N,N-dibutyl-2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)acetamide,
20 2-[2-(2,2-dimethylpropanoyl)-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl]-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
25 2-(8-(2,2-dimethylpropanoyl)-2-methoxy-9*H*-purin-9-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)-*N,N*-bis(3-methylbutyl)acetamide,
30 2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*c*][1,2,4]triazin-5-yl]-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-isobutyryl-5-methoxy-3*H*-imidazo[4,5-*b*]pyridin-3-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*c*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyridin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(8-isobutyryl-2-methoxy-9*H*-purin-9-yl)-*N,N*-bis(3-methylbutyl)acetamide,

- 2-(2-isobutyryl-6-methoxy-1*H*-imidazo[4,5-*b*]pyrazin-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(6-isobutyryl-3-methoxy-5*H*-imidazo[4,5-*c*]pyridazin-5-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-[6-(2,2-dimethylpropanoyl)-3-methoxy-5*H*-imidazo[4,5-*e*][1,2,4]triazin-5-yl]-*N,N*-bis(3-methylbutyl)acetamide,
- 5 1-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dibutylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-butyl-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
- 10 2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(*tert*-butyl)-*N*-ethylacetamide,
2-(2-benzoyl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-ethyl-*N*-1,3-thiazol-2-ylacetamide,
[6-methoxy-1-(3-methylbutyl)-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(2-ethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
[1-(3,3-dimethylbutyl)-6-methoxy-1*H*-benzimidazol-2-yl](phenyl)methanone,
- 15 *N*-benzyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-ethylacetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
N,N-dibutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N,N-diisobutyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-dipropylacetamide,
- 20 *N*-(cyclopropylmethyl)-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-(3-methylbutyl)acetamide,
N-butyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-cyclohexyl-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,
- 25 1-(1-{2-[trans-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(1-{2-[cis-2,5-dipropylpyrrolidin-1-yl]-2-oxoethyl}-6-methoxy-1*H*-benzimidazol-2-yl)-2,2-dimethylpropan-1-one,
1-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
- 30 *N*-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
N-butyl-2-(2-isobutyryl-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
N-(3,3-dimethylbutyl)-2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-propylacetamide,

- 2-[2-(2,2-dimethylpropanoyl)-6-methoxy-1*H*-benzimidazol-1-yl]-*N*-(2,2-dimethylpropyl)-*N*-ethylacetamide,
- 2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
- 2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-diisobutylacetamide,
- 5 5 *N*-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[4-(hydroxymethyl)benzoyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
- 2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
- 10 10 *N*-(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N*-propylacetamide,
- N*-(3,3-dimethylbutyl)-*N*-ethyl-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
- N,N*-bis(3,3-dimethylbutyl)-2-{2-[(4-trans-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}acetamide,
- 15 15 2-{2-[(4-cis-hydroxycyclohexyl)carbonyl]-6-methoxy-1*H*-benzimidazol-1-yl}-*N,N*-bis(3-methylbutyl)acetamide,
- 2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-bis(3-methylbutyl)acetamide,
- N,N*-dibutyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
- 20 20 2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N,N*-diisobutylacetamide,
- N*-(3,3-dimethylbutyl)-*N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)acetamide,
- 25 25 *N*-butyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
- N*-(3,3-dimethylbutyl)-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*-propylacetamide,
- N*-ethyl-2-(2-{[4-(hydroxymethyl)-1-methylcyclohexyl]carbonyl}-6-methoxy-1*H*-benzimidazol-1-yl)-*N*(3-methylbutyl)acetamide,
- 30 30 1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2,2-dimethylpropan-1-one,
- 1-{1-[2-(1-adamantyl)-2-oxoethyl]-6-methoxy-1*H*-benzimidazol-2-yl}-2-methylpropan-1-one,
- 1-(2-benzyl-5-methoxy-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,
- 1-(5-methoxy-2-phenyl-1*H*-benzimidazol-1-yl)-3,3-dimethylbutan-2-one,

1-[5-methoxy-2-(2-phenylethyl)-1*H*-benzimidazol-1-yl]-3,3-dimethylbutan-2-one,
or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

8. A method for treating ocular hypertension or glaucoma comprising
5 administration to a patient in need of such treatment a therapeutically effective amount of a compound of structural formula I of claim 1.

9. A method for treating macular edema, macular degeneration, increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension, and/or a
10 neuroprotective effect comprising administration to a patient in need of such treatment a pharmaceutically effective amount of a compound of claim 1; or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

10. A method of preventing repolarization or hyperpolarization of a mammalian cell
15 containing potassium channel or a method of treating Alzheimer's Disease, depression, cognitive disorders, and/or arrhythmia disorders in a patient in need thereof comprising administering a pharmaceutically effective amount of a compound according to Claim 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

20 11. A method of treating diabetes in a patient in need thereof comprising
administering a pharmaceutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof.

25 12. A composition comprising a compound of formula I of claim 1 and a pharmaceutically acceptable carrier.

13 The composition according to Claim 12 wherein the compound of formula I is applied as a topical formulation, said topical formulation administered as a solution or suspension and optionally containing xanthan gum or gellan gum.
30

14. A composition according to claim 13 wherein one or more of an active ingredient belonging to the group consisting of: β -adrenergic blocking agent, parasympatho-mimetic agent, sympathomimetic agent, carbonic anhydrase inhibitor, EP4 agonist, a prostaglandin or derivative thereof, hypotensive lipid, neuroprotectant, and/or 5-HT2 receptor agonist is optionally added.

15. A composition according to claim 14 wherein the β -adrenergic blocking agent is timolol, betaxolol, levobetaxolol, carteolol, or levobunolol; the parasympathomimetic agent is 5 pilocarpine; the sympathomimetic agent is epinephrine, brimonidine, iopidine, clonidine, or para-aminoclonidine, the carbonic anhydrase inhibitor is dorzolamide, acetazolamide, metazolamide or brinzolamide; the prostaglandin is latanoprost, travaprost, unoprostone, rescula, or S1033, the hypotensive lipid is lumigan, the neuroprotectant is eliprodil, R-eliprodil or memantine; and the 5-HT2 receptor agonist is 1-(2-aminopropyl)-3-methyl-1H-imidazol-6-ol fumarate or 2-(3-chloro-6-methoxy-10 indazol-1-yl)-1-methyl-ethylamine.